The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...

Sanofi (SNY) reported positive results from a Phase 3 study of its new subcutaneous formulation of Sarclisa in the treatment ...

China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, an ...

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma Approval based on positive pivotal ICARIA-MM phase 3 study using the China-bas ...

Among patients with relapsed/refractory multiple myeloma, fixed-dose subcutaneous treatment with ... Executive Vice President ...

(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least ...

Sanofi announces new Sarclisa subcutaneous formulation meets co-primary endpoints in IRAKLIA phase 3 study in multiple myeloma: Paris Friday, January 10, 2025, 15:00 Hrs [IST] Res ...

(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least ...